Clinical presentation of stage IIIA (N2) non-small cell lung cancer: role of multimodality therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10619518.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant chemotherapy before surgical resection of locally advanced non-small cell lung cancer (NSCLC) has been shown to improve survival compared with surgery alone in several randomized clinical trials. A case report is presented describing the use of paclitaxel and carboplatin in a multimodality regimen for a patient with stage IIIA N2 NSCLC. Studies are ongoing to determine the optimal type and timing of chemotherapy.
Medical subject headings
- Adenocarcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Neoadjuvant Therapy